Press Enter to search · Esc to close
A seven-marker aging clock built on nearly 60,000 blood samples and machine-learning screens for natural geroprotectors hint at a clinic-ready future for longevity medicine — with caveats.
Two Taiwanese medical societies just published joint guidelines reframing routine vaccines — flu, pneumococcal, shingles, COVID — as underused tools for preventing heart attacks and strokes in high-risk adults.
DNA-methylation clocks and a new atlas of immune aging are nudging longevity science from theory toward something a clinic could actually use. Here's where the evidence really stands.
Human genetics is guiding a fresh class of lipid drugs — Lp(a) inhibitors and lipoprotein-lipase activators — aimed at the residual heart risk statins can't reach.
A new European synthesis maps the levers — personal, clinical, and environmental — that may compress the years we spend sick at the end of a longer life.